EP300 and its paralog CBP play an important role in post-translational modification as histone acetyltransferases (HATs). EP300/CBP inhibition has been gaining attention as an anticancer treatment target in recent years. Herein, we describe the identification of a novel, highly selective EP300/CBP inhibitor, compound 11 (DS17701585), by scaffold hopping and structure-based optimization of a high-throughput
EP300 及其旁系同源 CBP 作为组蛋白乙酰转移酶 (HAT) 在翻译后修饰中发挥重要作用。近年来,EP300/CBP抑制作为抗癌治疗靶点受到关注。在这里,我们描述了一种新型的、高选择性的 EP300/CBP
抑制剂化合物11 ( DS17701585 ),通过支架跳跃和基于结构的优化高通量筛选命中1。化合物11 ( DS17701585 ) 在人肺鳞状细胞癌
细胞系 LK2 异种移植小鼠模型中显示出 SRY-box 转录因子 2 (SOX2) mRNA 表达的剂量依赖性抑制作用。